Market Overview

Pall Life Sciences' ForteBio Unveils Dip and Read Anti-Human Fab-CH1 Biosensor

Related PLL
Morgan Stanley Upgrades Danaher, Says Pall Deal Could Have 'Transformational Impact'
U.S. M&A Market: 5 Trends From The Month Of May
What to Expect from Pall (PLL) when it Reports Q4 Earnings? (Zacks)

ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read Anti-Human Fab-CH1 biosensor. The new biosensor enables an easy and rapid method for quantitation and kinetic characterization of human Fab, F(ab')2 and IgG – critical processes in drug discovery. Dip and Read biosensors are designed for use on ForteBio's Octet® and BLItz™ instrumentation systems.

Posted-In: News


Related Articles (PLL)

Get Benzinga's Newsletters